NMS·Healthcare·$474M·#493 / 520 in Healthcare
CCCC C4 Therapeutics, Inc.
18CRITICAL
CATEGORY BREAKDOWN
GROWTH2
QUALITY0
STABILITY44
VALUATION32
GOVERNANCE5
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+1.0%
2
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
9 months
25
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
23.4%
81
< 25% strong
Price / Sales
Market cap relative to trailing revenue
13.6x
32
< 3x strong
Rule of 40
Growth rate plus operating margin
-290
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
0.9%
7
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+55.7%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE CCCC WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when CCCC's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.